Disc Medicine (NASDAQ: IRON) CMO sells 5,731 shares under 10b5-1 plan

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Disc Medicine, Inc. Chief Medical Officer William Jacob Savage reported open-market sales of company stock. On April 13, 2026, he sold 3,531 shares of common stock at a weighted-average price of $66.1209 per share and a further 2,200 shares at $66.8073 per share, totaling 5,731 shares sold.

The filing states these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 2, 2025. After the sales, he continued to hold 79,480 shares of Disc Medicine common stock directly.

Insider Trade Summary 10b5-1

Net Seller: 5,731 shares ($380,449)

Net Sell 2 txns

Insider Savage William Jacob

Role Chief Medical Officer

Sold 5,731 shs ($380K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,531	$66.1209	$233K
Sale	Common Stock	2,200	$66.8073	$147K

Holdings After Transaction: Common Stock — 81,680 shares (Direct)

Footnotes (1)

These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 2, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.50 to $66.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.57 to $67.00, inclusive.

Key Figures

Shares sold (first tranche): 3,531 shares Price per share (first tranche): $66.1209 Shares sold (second tranche): 2,200 shares +3 more

6 metrics

Shares sold (first tranche) 3,531 shares Common Stock sale on April 13, 2026 at $66.1209

Price per share (first tranche) $66.1209 Weighted-average sale price for 3,531 shares on April 13, 2026

Shares sold (second tranche) 2,200 shares Common Stock sale on April 13, 2026 at $66.8073

Price per share (second tranche) $66.8073 Weighted-average sale price for 2,200 shares on April 13, 2026

Total shares sold 5,731 shares Net common stock sold across both transactions

Shares held after transactions 79,480 shares Direct common stock holdings after April 13, 2026 sales

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, Form 4, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 2, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"within the ranges set forth in footnotes (2) and (3) to this Form 4."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

non-derivative financial

"transaction_type: "non-derivative""

Form 4 Insider Transactions: What Each Field Means →

04/15/2026 - 05:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Savage William Jacob

(Last)

(First)

(Middle)

C/O DISC MEDICINE, INC.

321 ARSENAL STREET, SUITE 101

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Disc Medicine, Inc. [ IRON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/13/2026		S⁽¹⁾		3,531	D	$66.1209⁽²⁾	81,680	D
Common Stock	04/13/2026		S⁽¹⁾		2,200	D	$66.8073⁽³⁾	79,480	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 2, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.50 to $66.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.57 to $67.00, inclusive.

	By: /s/ Rahul Khara, as Attorney-in-Fact	04/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Disc Medicine (IRON) report for William Jacob Savage?

Disc Medicine’s Chief Medical Officer, William Jacob Savage, reported selling common stock in open-market transactions. On April 13, 2026, he sold a total of 5,731 shares of Disc Medicine common stock in two tranches at weighted-average prices in the mid-$66 range.

How many Disc Medicine (IRON) shares did the CMO sell and at what prices?

He sold 5,731 shares of Disc Medicine common stock. One sale covered 3,531 shares at a weighted-average price of $66.1209, and another covered 2,200 shares at a weighted-average price of $66.8073, with each sale executed as an open-market transaction.

How many Disc Medicine (IRON) shares does the CMO hold after these transactions?

Following the reported sales, William Jacob Savage directly held 79,480 shares of Disc Medicine common stock. The filing shows this remaining position after the second transaction on April 13, 2026, providing context for the size of the reported dispositions.

Were the Disc Medicine (IRON) insider stock sales under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 2, 2025. Such pre-arranged plans allow insiders to schedule trades in advance, helping separate trading decisions from day-to-day information flow.

What does the weighted-average price mean in the Disc Medicine (IRON) Form 4?

The weighted-average price reflects multiple trades executed within a price range on the same day. For one block, shares traded between $65.50 and $66.39; for the other, between $66.57 and $67.00. The insider offers to provide exact breakdowns upon request.

What type of Form 4 transactions did Disc Medicine (IRON) disclose for its CMO?

The company disclosed open-market sales of common stock coded as “S” transactions. Both entries involved non-derivative common shares, with no option exercises or derivative conversions reported, and were conducted directly in the market under the insider’s trading plan.